Walleye Capital
DAWN

Walleye Capital’s Day One Biopharmaceuticals DAWN Stock Holding History

Walleye Capital’s Portfolio DAWN Stock Details DAWN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-34,266
Closed -$477K – 4970
2024
Q3 		$477K Buy
+34,266
New +$489K ﹤0.01% 3335
2023
Q4 		– Sell
-277,206
Closed -$3.4M – 5045
2023
Q3 		$3.4M Buy
+277,206
New +$3.62M 0.01% 1323
2023
Q2 		– Sell
-16,519
Closed -$221K – 4420
2023
Q1 		$221K Buy
+16,519
New +$323K ﹤0.01% 2398
2022
Q2 		– Sell
-26,148
Closed -$259K – 2438
2022
Q1 		$259K Buy
+26,148
New +$345K 0.01% 1393

Other funds holding DAWN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
ECM
Estuary Capital Management Wayzata, Minnesota $598M AUM 1.72% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

Walleye Capital's DAWN Position: Q4 2024 in Review

Walleye Capital sold out of Day One Biopharmaceuticals (DAWN) in Q4 2024, closing a stake of 34,266 shares — an estimated $477K sold.

Walleye Capital first reported a position in DAWN in Q1 2022 and held it in 4 quarters. The position peaked at $3.4M in Q3 2023. 164 funds tracked by Wall St. Rank hold DAWN as of Q4 2024.

  • Walleye Capital reported no remaining Day One Biopharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Walleye Capital sold 34,266 Day One Biopharmaceuticals shares in Q4 2024, an estimated $477K.
  • Walleye Capital first reported a position in Day One Biopharmaceuticals in Q1 2022 and held it in 4 quarters.
  • Walleye Capital's Day One Biopharmaceuticals position peaked at $3.4M in Q3 2023.
  • 164 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q4 2024.

Based on Walleye Capital's 13F filing for Q4 2024, filed 13 Feb 2025.